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The antitubercular activity of rifampin was considerably increased when it was encapsulated in egg
phosphatidylcholine liposomes. A further increase in the activity was observed when the macrophage activator
tetrapeptide tuftsin was grafted on the surface of the drug-loaded liposomes. Intermittent treatments (twice
weekly) with these preparations were significantly more effective than the continuous treatments. Rifampin
delivered twice weekly for 2 weeks in tuftsin-bearing liposomes was at least 2,000 times more effective than the
free drug in lowering the load of lung bacilli in infected animals. However, pretreatment with drug-free
tuftsin-bearing liposomes did not render the pretreated animals resistant to the Mycobacterium tuberculosis
infections, neither did it appreciably increase the chemotherapeutic efficacy of the liposomized rifampin. These
results clearly demonstrate that liposome targeting to macrophages could considerably increase the antitu-
bercular activity of liposomized drugs such as rifampin. Also, it shows that immunoprophylactic treatment with
macrophage activators such as tuftsin does not afford any advantage in treatment of tuberculosis infections,
presumably because of inactivation of the primed macrophages by the mycobacterial sulfatides.
Tuberculosis is an infection which results in the largest
number of deaths worldwide; nearly 3 million people die of this
infection every year (9). The causative organism, Mycobacte-
rium tuberculosis, resides and proliferates primarily within
mononuclear phagocytes, which normally serve as the first line
of defense against infections (2). The most important factor in
the treatment of tuberculosis is prolonged chemotherapy,
which is often associated with serious and unwanted side
effects (3, 20). Also, undesired effects may be caused by the
high levels of antitubercular drugs in blood required to achieve
an effective intracellular drug concentration. Keeping this in
view, it is desirable to develop an approach which would allow
the use of lower drug doses by delivering the agent to the
infected cells, thereby improving efficacy and potentially reduc-
ing toxicity.
Tuftsin is a tetrapeptide (Thr-Lys-Pro-Arg) which is an
integral component of the leukophilic immunoglobulin G
(residues 289 to 292) and is released physiologically as the free
peptide fragment after enzymatic cleavage (8). The peptide is
known to bind specifically to macrophages/monocytes and also
to potentiate the natural killer activity of these cells (8). Our
earlier studies have shown that incorporation of this tetrapep-
tide in liposome bilayers, after its modification at the C
terminus (17), increases not only its macrophage-activating
property (16) but also liposome uptake by macrophages (17).
The liposomes thus formed have been shown to be quite
effective as drug vehicles in treatment of leishmaniasis (6) and
aspergillosis (12). Also, pretreatment of animals with these
liposomes has been found to render them resistant to a variety
of infections (4, 6, 12). To further evaluate the usefulness of
these liposomes as drug vehicles in the treatment of macro-
phage-based infections, we have now examined their suitability
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as rifampin (RFP) vehicles in treatment of tuberculosis in
mice.
MATERUILS AND METHODS
Materials. Egg phosphatidylcholine was isolated and puri-
fied by published procedures (18). Tuftsin modified by attach-
ment of a palmitoyl residue to its C terminus through an
ethylenediamine spacer arm (Thr-Lys-Pro-Arg-NH-(CH2)2-
NH-CO-C15H31) was prepared as described previously (17).
RFP was bought from Sigma Chemical Co.
Liposomes. Egg phosphatidylcholine (62.5 ,umol) and RFP
(0.61 pmol), in the presence and absence of modified tuftsin (7
to 8% by egg phosphatidylcholine weight), were dissolved in
chloroform, and the solution was dried in a glass tube under a
slow jet of nitrogen, resulting in formation of a thin lipid film
on the wall of the tube. Final traces of the solvent were
removed by leaving the film in vacuo overnight at 4°C. To the
tube was added 1.5 ml of phosphate-buffered saline (PBS; 10
mM phosphate containing 150 mM NaCl [pH 7.4]) containing
1.5 mg of RFP, and the mixture was vortexed at 35 to 40°C for
15 to 20 min. The lipid dispersion thus obtained was trans-
ferred to a cuvette and sonicated for 30 min under nitrogen,
using a probe-type sonicator (W-220 F; Heat Systems). The
sonicated preparation was centrifuged at 12,000 x g in an IEC
refrigerated centrifuge for 30 min to remove titanium particles
as well as undispersed lipids. The supernatant was carefully
withdrawn and gel filtered through a Sephadex G-50 column
(40 by 1.5 cm), with PBS as the eluant, to separate liposomized
RFP (Lip-RFP) from free RFP. The Lip-RFP was eluted in the
void volume. The liposome-rich fractions were pooled and
concentrated in an Amicon Centriflo CF-25 cone. The outer
diameter of liposomes, as determined by electron microscopy,
ranged between 25 and 65 nm. About 28 to 32% of RFP was
found to be incorporated in the liposomes.
RFP and tuftsin estimation. We estimated the RFP concen-
tration by measuring its A334. We determined the amount of
liposomized drug after lysing the liposomes with Triton X-100
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(1%). The RFP A334 was found to remain unaffected by the
presence of liposomes and detergent and was linear up to 100
,ug of RFP. The amount of tuftsin incorporated in liposomes
was estimated as described previously (17). The incorporation
efficiency was found to be about 98%.
RFP localization in liposomes. To determine whether RFP
is entrapped or intercalated in liposomes, we froze the lipo-
some preparation in liquid nitrogen and immediately thawed
it. The preparation was gel filtered again through the Sephadex
G-50 column. RFP eluted under two different peaks, one
corresponding to the Lip-RFP (about 40%) and the other
corresponding to free RFP (about 60%).
Animals. Swiss albino mice weighing 20 ± 2 g were used in
the study. The animals were given standard pellet diet (Hin-
dustan Lever Ltd., Bombay, India) and water ad libitum.
Mycobacteria. M. tuberculosis H37RV, equivalent to ATCC
25618-H37RV, was procured from the Trudeau Mycobacterial
Culture Collection Centre, Trudeau Institute Inc., Saranac
Lake, N.Y. It was maintained on Lowenstein-Jensen medium
through routine bimonthly passage.
Infection. Mycobacterial growth (18 to 21 days old) main-
tained on Lowenstein-Jensen medium was harvested. It was
weighed, and a 5-mg/ml suspension was prepared by homoge-
nizing the culture in sterile saline containing 0.05% Tween 80.
A 1-mg amount of culture was equivalent to about 109 CFU as
determined from a sample of suspension plated to confirm the
number of viable bacilli. Mice were infected intravenously by
injection of about 109 CFU or 0.2 ml of the above suspension
via the tail vein. Glass beads were added to the suspension to
prevent clumping of the hydrophobic mycobacteria. Mice
developed 3+ infection by 13 to 16 days and lost weight during
progression of the infection. The animals in the control group
were given saline by the same route.
Assessment of parameters. The number of bacilli in lungs,
livers, and spleens of mice was quantitated by measuring CFU.
Three animals from each group (8 to 12 animals per group)
were sacrificed by cervical dislocation 3 days after the last dose.
The spleens, livers, and lungs were aseptically removed and
weighed. These organs from three different animals were
separately pooled and homogenized in sterile saline. Serial
twofold dilutions of the homogenates were prepared in sterile
saline, inoculated onto duplicate set of slants of Lowenstein-
Jensen medium, and incubated for 15 to 21 days at 37°C. After
appearance of visible growth, the isolated colonies were
counted and the number of live bacilli was calculated in the
original dilutions.
Mean survival time (MST) was considered to be a parameter
in all single treatments and prophylactic studies. The animals
that were left (five to nine mice per group) after the CFU
count were observed up to day 30 postinfection for calculation
of MST. In the multitreatment studies, this parameter was not
considered since no mortality was observed in the treated
groups up to day 30 after the infection. Lung weight per 100 g
of mice was considered to be a parameter in some experiments
(5). The degree of lung damage was determined by the
morphometric analysis as described by Weibel (19).
Treatment. In the first set of experiments, the infected mice
were given a single intravenous dose of RFP, whereas in the
second set, the animals were given four doses of RFP at 10
mg/kg/day either on consecutive days or twice weekly for 2
weeks. Treatment was begun 3 days after the infection in each
case.
Statistical analysis. Statistical significance (P value) was
determined by using F and t statistics. The means of two data
sets were compared by using the two-sided F-ratio test and t
test. The F-ratio test determined whether the standard devia-
tions of two data sets were equal, and accordingly an appro-
priate t test was applied (7).
RESULTS
Initially, experiments were done to optimize the RFP dose,
after encapsulation in liposomes, for producing the maximum
effect against the M. tuberculosis infections. For this purpose,
different doses (3, 5, and 10 mg/kg) of Lip-RFP were intrave-
nously delivered to M. tuberculosis-infected mice, and the
antitubercular response was measured as described in Materi-
als and Methods. The lung bacillus load, lung weight, MST,
and percent lung damage were considered the main parame-
ters to assess the antitubercular activity. At low doses (<10
mg/kg), the antitubercular response of Lip-RFP was not much
different from that of free RFP, but at a 10-mg/kg dose of
Lip-RFP, a significant reduction in the lung bacillus load and
an increase in MST were observed (Table 1) compared with
those in untreated (P < 0.01) or free-RFP-treated (P < 0.01)
animals.
To further enhance the efficacy of Lip-RFP against the
tuberculosis infections, we explored the effects of the route of
administration, liposome surface charge, cholesterol content,
and multiple treatments on the antitubercular activity. Chang-
ing the route of administration from intravenous to intraperi-
toneal, the liposome surface charge from neutral to positive,
and the cholesterol content from 0 to 25 mol% did not further
increase the RFP activity (data not shown). However, Lip-RFP
appeared to be appreciably better (P < 0.05) than free RFP in
lowering the lung bacillus load when up to four doses of this
preparation were delivered on consecutive days (Table 2).
Markedly better effects (P < 0.01) of Lip-RFP than free RFP
were observed when the multiple treatment was given inter-
mittently rather than continuously; both the lung bacillus load
and lung weight were significantly reduced by administration of
Lip-RFP twice weekly for 2 weeks (Table 3). That the inter-
mittent treatment with Lip-RFP was more effective than the
treatment with free RFP was further evident from the mor-
phometric data (Table 3), which showed that the lungs were
only 8% tuberculoid compared with 20% with free RFP.
Since grafting of tuftsin on the liposome surface is expected
to increase liposome uptake by the macrophages, we evaluated
the antitubercular response of RFP after encapsulating it in
tuftsin-bearing liposomes (Tuft-Lip-RFP). Although the single
treatment with Tuft-Lip-RFP was only marginally better than
that observed with Lip-RFP (Table 4), Tuft-Lip-RFP given
twice weekly for 2 weeks was considerably more effective (P <
0.05) than Lip-RFP in controlling tuberculosis (Table 5).
Because incorporation of tuftsin into the liposome bilayer
increases the ability of tuftsin to increase the nonspecific
resistance against infections and uptake by the macrophages,
we thought it appropriate to study the effect of Tuft-Lip
pretreatment on the establishment and course of M. tubercu-
losis infections. Pretreatment with Tuft-Lip (50 ,ug of tuftsin
per day per animal) was administered on days 1 to 3 prior to
the infection. Results of these experiments (not shown) re-
vealed that the Tuft-Lip pretreatment did not significantly
affect the establishment and course of the infection or the
chemotherapeutic efficacy of Lip-RFP.
DISCUSSION
The high excretion rate is the major problem associated with
the use of RFP as an antimycobacterial agent (15), because it
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TABLE 1. Efficacy of Lip-RFP against M. tuberculosis infection in mice
Log CFUb in:
Group and expt" MST (days)
Lungs Liver Spleen
Lip-RFP
a 7.61 5.86 6.23 22.9
b 8.65 6.79 6.60 19.6
c 7.87 6.81 6.91 19.8
(8.04 ± 0.44) (6.48 ± 0.44) (6.58 ± 0.27) (20.76 ± 1.50)
Free RFP
a 9.83 5.81 6.45 17.3
b 9.57 6.61 7.52 17.3
c 9.48 7.07 6.95 16.4
(9.62 ± 0.15) (6.49 ± 0.52) (6.97 ± 0.44) (17.00 ± 0.42)
Control
a 11.30 7.03 6.86 13.5
b 10.85 6.23 8.32 14.6
c 9.60 7.23 8.92 14.1
(10.58 ± 0.72) (6.83 ± 0.43) (8.03 ± 0.86) (14.06 ± 0.45)
P value
Lip-RFP vs free RFP <0.01 >0.05 >0.05 <0.01
Lip-RFP vs control <0.01 >0.05 <0.05 <0.01
Free RFP vs control >0.05 >0.05 >0.05 <0.01
"a, b, and c denote three different experiments.b The CFU in each experiment was determined by separately pooling different organs from three different animals. Values shown in parentheses are mean ± standard
deviation.
necessitates daily administration of a high dose, which often
leads to serious toxic side effects such as hepatotoxicity (14).
Because liposomes have an inherent tendency to localize
mainly in the cells (1) that also serve as the host for M.
tuberculosis, encapsulation of RFP in liposomes may help to
reduce the daily drug dose by concentrating the drug in these
cells. That this may indeed be the case is well supported by our
finding that Lip-RFP given at 10 mg/kg is appreciably more
effective than the free drug in controlling the tuberculosis
infections. It is also supported by results of an earlier study
TABLE 2. Efficacy of four continuous doses of Lip-RFP given on days 3, 4, 5 and 6 postinfection against M. tuberculosis infection in mice
Log CFUb in:
Group and expt"
Lungs Liver Spleen
Lip-RFP
a 6.48 4.48 4.10
b 6.64 5.97 6.11
c 6.48 4.30 5.60
(6.53 ± 0.07) (4.92 ± 0.75) (5.27 ± 0.85)
Free RFP
a 6.67 5.04 4.30
b 7.48 6.40 6.70
c 7.70 5.60 5.78
(7.28 ± 0.44) (5.68 ± 0.56) (5.59 ± 0.98)
Control
a 9.51 5.04 6.75
b 9.66 6.78 7.81
c 9.85 7.30 7.90
(9.67 ± 0.14) (6.37 ± 0.96) (7.48 ± 0.52)
P value
Lip-RFP vs free RFP <0.05 >0.05 >0.05
Lip-RFP vs control <0.01 >0.05 <0.01
Free RFP vs control <0.01 >0.05 <0.05
aa, b, and c denote three different sets of experiments.h CFU in each experiment was determined by separately pooling different organs from three different animals. Values shown in parentheses are mean ± standard
deviation.
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TABLE 3. Efficacy of intermittent treatment with Lip-RFP given twice weekly for 2 weeks against M. tuberculosis infection in mice
Log CFUh in: Lung wt Morphometric analysis of lung
Group and expt"' Log_in:Lun(gIOO g of (vol/vol% lung parenchyma)":
Lungs Liver Spleen body wt) Normal Tubercular
Lip-RFP
a 7.00 4.30 5.60 2.10 91.5 ± 5.4 8.5 ± 5.4
b 6.95 4.78 5.00 1.13
(6.97 ± 0.02) (4.54 ± 0.24) (5.30 ± 0.30) (1.61 ± 0.48)
Free RFP
a 8.60 5.20 6.08 2.22 81.0 ± 3.8 19.0 ± 3.8
b 8.66 5.28 6.18 1.27
(8.63 ± 0.03) (5.24 ± 0.04) (6.13 ± 0.05) (1.74 ± 0.47)
Control
a 9.30 7.30 7.90 3.39 29.0 ± 2.3 71.0 ± 2.3
b 10.30 5.60 6.83 1.81
(9.80 ± 0.50) (6.45 ± 0.85) (7.36 ± 0.53) (2.60 ± 0.79)
P values
Lip-RFP vs free RFP <0.01 <0.05 <0.05 >0.05 >0.05
Lip RFP vs control <0.01 <0.05 <0.05 >0.05 <0.01
Free RFP vs. control <0.05 >0.05 <0.05 >0.05 <0.01
aa and b denote two different sets of experiments.h CFU in each experiment was determined by separately pooling different organs from three different animals. Values shown in parentheses are mean ± standard
deviation.
' Morphometric analysis, for determining the lung damage, was carried out on three animals, and values are expressed as mean ± standard deviation.
(11), which showed significantly better antitubercular effects of RFP is perhaps due to the ability of liposomes to localize
a combination of isoniazid and RFP after their encapsulation preferentially in macrophages/monocytes, leading to a high
in liposomes. intracellular drug concentration. This is quite consistent with
The better antitubercular response of Lip-RFP than of free our finding that intermittent but not continuous treatment with
TABLE 4. Efficacy of Tuft-Lip-RFP against M. tuberculosis infection in mice
Log CFUb in: Lung wt (g/100 g
Group andexptL' Lie Spleen MST (days) of body wt)
Lungs Liver Spleen
Tuft-Lip-RFP
a 6.60 6.59 6.97 25.6 0.97
b 6.04 5.45 5.60 26.7 1.27
(6.32 ± 0.28) (6.02 ± 0.57) (6.28 ± 0.68) (26.15 ± 0.55) (1.12 ± 0.15)
Lip-RFP
a 7.41 6.38 6.13 25.0 1.18
b 7.15 5.89 5.90 27.8 1.33
(7.28 ± 0.13) (6.13 ± 0.24) (6.01 ± 0.11) (26.40 ± 1.40) (1.25 ± 0.07)
Tuft-Lip
a 9.00 7.02 6.76 17.1 1.24
b 8.60 5.99 6.01 20.1 1.45
(8.80 ± 0.20) (6.50 ± 0.51) (6.38 ± 0.37) (18.60 ± 1.50) (1.34 ± 0.10)
Control
a 9.08 8.08 7.20 15.7 1.30
b 9.60 5.83 6.34 18.2 1.56
(9.34 ± 0.26) (6.95 ± 1.12) (6.77 ± 0.43) (16.95 ± 1.25) (1.43 ± 0.13)
P value
Tuft-Lip-RFP vs Lip-RFP <0.05 >0.05 >0.05 >0.05 >0.05
Tuft-Lip-RFP vs Tuft-Lip <0.01 >0.05 >0.05 <0.01 >0.05
Tuft-Lip-RFP vs control <0.01 >0.05 >0.05 <0.01 >0.05
Lip-RFP vs Tuft-Lip <0.01 >0.05 >0.05 <0.01 >0.05
aa and b denote two different sets of experiments.h CFU in each experiment was determined by separately pooling organs from three different animals. Values shown in parentheses are mean ± standard deviation.
VOL. 38, 1994
ANTIMICROB. AGENTS CHEMOTHER.
TABLE 5. Efficacy of intermittent treatment with Tuft-Lip-RFP given twice weekly for 2 weeks
Group and expt" Log CFU in": Lung wt (g/100 g
Lungs Liver Spleen of body wt)
Tuft-Lip-RFP
a 7.73 4.85 5.70 2.26
b 6.85 4.30 5.08 2.00
(7.29 ± 0.44) (4.57 ± 0.27) (5.39 ± 0.31) (2.13 ± 0.13)
Lip-RFP
a 9.28 6.26 6.60 2.63
b 8.48 5.30 5.90 2.35
(8.88 ± 0.40) (5.78 ± 0.48) (6.25 ± 0.35) (2.49 ± 0.14)
Control
a 13.08 7.85 8.48 5.67
b 11.40 7.60 7.87 4.75
(12.24 ± 0.84) (7.72 ± 0.12) (8.17 ± 0.30) (5.21 ± 0.46)
P value
Tuft-Lip-RFP vs Lip- <0.05 >0.05 >0.05 >0.05
RFP
Tuft-Lip-RFP vs control <0.01 <0.01 <0.01 <0.01
Lip-RFP vs control <0.01 <0.01 <0.01 <0.01
aa and b denote two different sets of experiments.
" CFU in each experiment was determined by separately pooling different organs from three different animals. Values shown in parentheses are mean ± standard
deviation.
Lip-RFP was considerably more (about 50-fold) effective than
that with free drug under identical conditions (Table 3). Also,
it suitably explains our present observation that incorporation
of tuftsin in the liposome bilayer leads to a further increase
(about 40-fold) in the antitubercular activity of Lip-RFP
(Table 5).
Orozco et al. (10) have determined the distribution of
Lip-RFP in mice, which showed a marked difference after
infection of the animals with tuberculosis. A relatively higher
liposome concentration in lungs, kidneys, and blood was
observed in tuberculosis-infected mice, whereas the maximum
concentration in the uninfected animals was in the liver and
spleen. Furthermore, these authors observed a longer reten-
tion of liposomes by the infected tissue. These findings could
explain our observation of the greater efficacy of Lip-RFP in
the lungs, since in all our experiments the lungs were the
organs showing tubercle formation with the highest bacillus
load.
Tuftsin potentiates the natural killer activity of the macro-
phages and other phagocytosing cells and has been shown to
enhance the nonspecific resistance of the host against parasitic
and fungal infections (4, 6, 12). However, in the present study
the immunoprophylactic treatment with Tuft-Lip did not prove
very effective against tuberculosis infections. The observed
failure of this treatment in providing resistance against tuber-
culosis infections could be attributed primarily to the presence
in the mycobacterial cell wall of some sulfolipids which are
known to inhibit macrophage activity (13).
In summary, we have demonstrated that Lip-RFP is more
effective than free RFP in controlling M. tuberculosis infections
in mice. This increased antitubercular response of Lip-RFP is
further increased by incorporating tuftsin in the liposome
bilayer. From these results, we conclude that homing of
liposomes to macrophages may considerably improve the
therapeutic efficacy of the liposomized antitubercular drugs.
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